Disseminated intravascular coagulation

被引:228
作者
Levi, Marcel [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med & Internal Med, NL-1012 WX Amsterdam, Netherlands
关键词
disseminated intravascular coagulation; coagulation; fibrinolysis; tissue factor; blood coagulation factor inhibitors; multiple organ failure;
D O I
10.1097/01.CCM.0000281468.94108.4B
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To review the current knowledge on the clinical manifestation, pathogenesis, diagnosis, and management of disseminated intravascular coagulation (DIC). Data Source: Selected articles from the MEDLINE database. Data Synthesis: DIC may complicate a variety of disorders and can cause significant morbidity (in particular related to organ dysfunction and bleeding) and may contribute to mortality. The pathogenesis of DIC is based on tissue factor-mediated initiation of systemic coagulation activation that is insufficiently contained by physiologic anticoagulant pathways and amplified by impaired endogenous fibrinolysis. The diagnosis of DIC can be made using routinely available laboratory tests and scoring algorithms. Supportive treatment of DIC may be aimed at replacement of platelets and coagulation factors, anticoagulant treatment, and restoration of anticoagulant pathways. Conclusions: Insight into the pathogenesis of DIC has resulted in better strategies for clinical management, including straightforward diagnostic criteria and potentially beneficial supportive treatment options.
引用
收藏
页码:2191 / 2195
页数:5
相关论文
共 52 条
[1]   Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study [J].
Abraham, E ;
Reinhart, K ;
Svoboda, P ;
Seibert, A ;
Olthoff, D ;
Dal Nogare, A ;
Postier, R ;
Hempelmann, G ;
Butler, T ;
Martin, E ;
Zwingelstein, C ;
Percell, S ;
Shu, V ;
Leighton, A ;
Creasey, AA .
CRITICAL CARE MEDICINE, 2001, 29 (11) :2081-2089
[2]   Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial [J].
Abraham, E ;
Reinhart, K ;
Opal, S ;
Demeyer, I ;
Doig, C ;
Rodriguez, AL ;
Beale, R ;
Svoboda, P ;
Laterre, PF ;
Simon, S ;
Light, B ;
Spapen, H ;
Stone, J ;
Seibert, A ;
Peckelsen, C ;
De Deyne, C ;
Postier, R ;
Pettilä, V ;
Sprung, CL ;
Artigas, A ;
Percell, SR ;
Shu, V ;
Zwingelstein, C ;
Tobias, J ;
Poole, L ;
Stolzenbach, JC ;
Creasey, AA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02) :238-247
[3]   Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].
Abraham, E ;
Laterre, P ;
Garg, R ;
Levy, H ;
Talwar, D ;
Trzaskoma, BL ;
Francois, B ;
Guy, JS ;
Bruckmann, M ;
Rea-Neto, A ;
Rossaint, R ;
Perrotin, D ;
Sablotzki, A ;
Arkins, N ;
Utterback, BG ;
Macias, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341
[4]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[5]  
BAUER KA, 1987, BLOOD, V70, P343
[6]   Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis [J].
Bernard, GR ;
Margolis, BD ;
Shanies, HM ;
Ely, EW ;
Wheeler, AP ;
Levy, H ;
Wong, K ;
Wright, TJ ;
Ahmed, M ;
Albertson, T ;
Anas, N ;
Astiz, M ;
Bacon, A ;
Bandi, V ;
Booth, F ;
Bray, W ;
Brilli, R ;
Carlson, R ;
Cheatham, M ;
Conrad, S ;
Cooney, R ;
Cox, M ;
Dolich, M ;
Dries, D ;
Fang, R ;
Forse, R ;
Fricker, R ;
Givens, C ;
Gomez, C ;
Gottlieb, J ;
Graham, D ;
Cropper, I ;
Cross, T ;
Harrison, N ;
Kearl, R ;
Kearney, P ;
Kinasewitz, G ;
Kruse, J ;
Lamberti, J ;
Levy, M ;
Light, R ;
Lin, L ;
Lisco, S ;
Lo, T ;
Linda, L ;
Lodato, R ;
Malave, L ;
Martinez, A ;
Mastuschak, G ;
McDermott, L .
CHEST, 2004, 125 (06) :2206-2216
[7]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[8]   GRAM-POSITIVE ORGANISMS AND SEPSIS [J].
BONE, RC .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) :26-34
[9]   DIAGNOSIS OF DISSEMINATED INTRAVASCULAR COAGULATION - ROLE OF D-DIMER [J].
CARR, JM ;
MCKINNEY, M ;
MCDONAGH, J .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 91 (03) :280-287
[10]  
COLMAN RW, 1990, SEMIN ONCOL, V17, P172